Keep the QT interval: It is a reliable predictor of ventricular arrhythmias

Heart Rhythm

Volumn 5, Issue 8, 2008, Pages 1213-1215

  Roden, Dan M ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiarrhythmic drugs; Cellular and molecular mechanisms; Congenital long QT syndrome; QT prolongation; Torsades de pointes; Ventricular repolarization

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; DOFETILIDE; IBUTILIDE; MOXIFLOXACIN; RANOLAZINE; SOTALOL; TERFENADINE; VERAPAMIL; ZIPRASIDONE;

ARRHYTHMOGENESIS; ARTICLE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG MECHANISM; ELECTROCARDIOGRAPHY; EVIDENCE BASED MEDICINE; HEART DEATH; HEART REPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; HUMAN; LONG QT SYNDROME; NONLINEAR SYSTEM; PREDICTION; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RELIABILITY; SUDDEN DEATH; TORSADE DES POINTES;

ARRHYTHMIAS, CARDIAC; HEART CONDUCTION SYSTEM; HUMANS; LONG QT SYNDROME; PROGNOSIS; RISK FACTORS; TACHYCARDIA, VENTRICULAR; TIME FACTORS; VENTRICULAR FIBRILLATION;

EID: 50949102066     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2008.05.008     Document Type: Article

References (10)

1. Woosley R.L., Chen Y., Freiman J.P., et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 269 (1993) 1532-1536
2. Honig P.K., Wortham D.C., Zamani K., et al. Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. JAMA 269 (1993) 1513-1518
3. Pratt C.M., Ruberg S., Morganroth J., et al. Dose-response relation between terfenadine (Seldane) and the QTc interval on the scalar electrocardiogram: distinguishing a drug effect from spontaneous variability. Am Heart J 131 (1996) 472-480
4. Priori S.G., Schwartz P.J., Napolitano C., et al. Risk stratification in the long-QT syndrome. N Engl J Med 348 (2003) 1866
5. Straus S.M., Kors J.A., De Bruin M.L., et al. Prolonged QTc interval and risk of sudden cardiac death in a population of older adults. J Am Coll Cardiol 47 (2006) 362-367
6. Singh S., Zoble R.G., Yellen L., et al. Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 102 (2000) 2385-2390
7. Soyka L.F., Wirtz C., and Spangenberg R.B. Clinical safety profile of sotalol in patients with arrhythmias. Am J Cardiol 65 (1990) 74A-81A
8. Ellenbogen K.A., Stambler B.S., Wood M.A., et al. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 28 (1996) 130-136
9. Darbar D., Kimbrough J., Jawaid A., et al. Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome. J Am Coll Cardiol 51 (2008) 836-842
10. Kamiya K., Niwa R., Mitcheson J.S., et al. Molecular determinants of hERG channel block. Mol Pharm 69 (2006) 1709-1716